AbbVie and OSE Collaborate on OSE-230 Monoclonal Antibody for Chronic Inflammation

Photo:Representative Image

AbbVie Inc. and OSE Immunotherapeutics SA, a clinical-stage immunotherapy company, announced a strategic partnership to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in pre-clinical development.

OSE-230 is a first-in-class monoclonal antibody designed to activate ChemR23, a G-Protein Coupled Receptor (GPCR) target. Activation of ChemR23 may offer a novel mechanism for resolving chronic inflammation, modulating the functions of both macrophages and neutrophils.

"This collaboration underscores our commitment to expanding our immunology portfolio with the ultimate goal of improving the standard of care for patients living with inflammatory diseases globally," said Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research, AbbVie. "By leveraging our expertise in immunology drug development, we look forward to advancing OSE-230, which offers a novel mechanism of action to treat chronic inflammation."

"We are very pleased to collaborate with AbbVie, a global leader in the development and commercialization of innovative medicines, to drive our OSE-230 program forward," said Nicolas Poirier, chief executive officer of OSE Immunotherapeutics. "This partnership represents a major milestone in our company's progress and recognizes the value of our innovative RandD capabilities. I want to thank our employees who helped us achieve this milestone."

Under the terms of the agreement, AbbVie has an exclusive worldwide license to develop, manufacture and commercialize OSE-230. OSE Immunoterapia will receive an additional $48 million. Front. For OSE immunotherapy and an additional $665 million for clinical development, regulatory and commercial activities, and available fees. Rodino Antitrust Improvements Act.